Research Article
American Journal of BioMedicine
Volume 12, Issue 3, 2024, Pages 67- 82 
10.18081/2333-5106/2024.12/67
Daniela Landon, 
, M Azoicăi , V SoRelle 1 *
Received 22 May 2023; revised 09 July 2024; accepted 21 July 2024; published 15 August 2024
Abstract
The objective of this study was to evaluate the most important gene and miRNA mutations involved in the development of acute lymphoblastic leukaemia (ALL) in Romania and their potential to serve as patients’ prognostic biomarkers of early response to therapy and treatment outcome. A comparative analysis was performed to evaluate the susceptibility to ALL in the context of genetic factors such as somatic mutations and gene expression mutations in B-cell precursor (BCP) ALL. To achieve this aim, a retrospective study involving 73 Romanian BCP ALL patients was conducted, and the influence of genetic defects on basic clinical and immune-phenotypic characteristics was evaluated. The presence of mutations in FLT3, NRAS, PIK3CA, and KMT2A genes and their combinations were tested for associations with clinical parameters and the influence on the overall survival (OS) and event-free survival (EFS) of BCP ALL Romanian patients after therapy initiation. Gene expression profiling for the miRNA genes miR-18b, miR-19b, miR-222, and miR-423-5p and their influence on the OS and EFS of 48 BCP ALL Romanian patients were evaluated. The cumulative results suggest that the point mutations C1543T (pro537ser in the Flt3 receptor protein, rs786202394) and G3-4A (rs786202383) in the tyrosine kinase domain of the Flt3 receptor, and the somatic mutation c.64C>G in the codon 22 of the KMT2A gene may play a role in the susceptibility of Romanian patients with BCP ALL to develop the disease, affecting the prognosis of the patients. Unexpectedly, the negative prognosis of the mutation C1543T (pro537ser) in the Flt3 receptor protein was correlated with the good response to therapy and considered a favourable marker. Gene expression profiling analysis indicated that low expression levels of miR-223.3p and miR-222-3p could serve as adverse prognostic factors in BCP ALL, representing possible targets for therapy. In conclusion, this is the first study performed on the Romanian population that evaluates the influence of gene and miRNA mutations on the occurrence and prognosis of BCP ALL.
Keywords: Acute lymphoblastic leukaemia (ALL); Flt3 receptor protein; BCP ALL
Copyright © 2024 SoRelle, et al. This article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cited by CrossRef (2)
Cited by Scopus (0)
| 1. Follini E, Marchesini M, Roti G. Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia. Int. J. Mol. Sci. 2019;20:3021. https://doi.org/10.3390/ijms20123021 |
| 2. Kakaje A, Marwan Alhalabi M, Ghareeb A, Karam B et al. Rates and trends of childhood acute lymphoblastic leukaemia: an epidemiology study. 2020. ncbi.nlm.nih.gov https://doi.org/10.1038/s41598-020-63528-0 |
| 3. Raetz E.A., Teachey D.T. T-cell acute lymphoblastic leukemia. Hematology. 2016;2016:580-588. https://doi.org/10.1182/asheducation-2016.1.580 |
| 4. Pommert L, Burns R, Furumo Q, Pulakanti K et al. Novel germline TRAF3IP3 mutation in a dyad with familial acute B lymphoblastic leukemia. 2021. ncbi.nlm.nih.gov https://doi.org/10.1002/cnr2.1335 |
| 5. Allen A., Sireci A., Colovai A., Pinkney K., Sulis M., Bhagat G., Alobeid B. Early T-cell precursor leukemia/lymphoma in adults and children. Leuk. Res. 2013;37:1027-1034. https://doi.org/10.1016/j.leukres.2013.06.010 |
| 6. Mroczek A, Zawitkowska J, Kowalczyk J, Lejman M. Comprehensive Overview of Gene Rearrangements in Childhood T-Cell Acute Lymphoblastic Leukaemia. 2021. ncbi.nlm.nih.gov https://doi.org/10.3390/ijms22020808 |
| 7. Szczepański T., van der Velden V.H.J., van Dongen J.J.M. Classification systems for acute and chronic leukemias. Best Pract. Res. Clin. Haematol. 2003;16:561-582. https://doi.org/10.1016/S1521-6926(03)00086-0 |
| 8. Lejman M, Chałupnik A, Chilimoniuk Z, Dobosz M. Genetic Biomarkers and Their Clinical Implications in B-Cell Acute Lymphoblastic Leukemia in Children. 2022. ncbi.nlm.nih.gov https://doi.org/10.3390/ijms23052755 |
| 9. Van Vlierberghe P, Palomero T, Khiabanian H, et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat. Genet. 2010;42:338-342. https://doi.org/10.1038/ng.542 |
| 10. Xiang J, Wang G, Xia T, Chen Z. The depletion of PHF6 decreases the drug sensitivity of T-cell acute lymphoblastic leukemia to prednisolone. Biomed. Pharmacother. 2019;109:2210-2217. https://doi.org/10.1016/j.biopha.2018.11.083 |
| 11. Hong FD, Huang HJ, To H, et al. Structure of the human retinoblastoma gene. Proc. Natl. Acad. Sci. USA. 1989;86:5502-5506. https://doi.org/10.1073/pnas.86.14.5502 |
| 12. Hofman I, Patchett S, Van Duin M, et al. Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma. Haematologica. 2017;102:e317-e320. https://doi.org/10.3324/haematol.2016.162198 |
| 13. De Keersmaecker K, Atak Z.K, Li N, Vicente C, et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat. Genet. 2013;45:186-190. https://doi.org/10.1038/ng.2508 |
| 14. Kampen KR, Sulima SO, Verbelen B, et al. The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL. Leukemia. 2018;33:319-332. https://doi.org/10.1038/s41375-018-0176-z |
| 15. Kuz JB, Rausch T, Bandapalli OR, et al. Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation. Haematologica. 2015;100:1442-1450. https://doi.org/10.3324/haematol.2015.129692 |
| 16. Cortés-Ciriano I, Lee JJ.-K, et al. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat. Genet. 2020;52:331-341. |
| 17. Karrman K, Johansson B. Pediatric T-cell acute lymphoblastic leukemia. Genes Chromosom. Cancer. 2017;56:89-116. https://doi.org/10.1002/gcc.22416 |
| 18. Ratnaparkhe M, Hlevnjak M, Kolb T, et al. Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis. Leukemia. 2017;31:2048-2056. https://doi.org/10.1038/leu.2017.55 |
| 19. Khondkaryan L, Andreasyan D, Hakobyan Y, Eylül Bankoglu E et al. Incidence and Risk Factors of Acute Leukemias in Armenia: A Population-Based Study. 2022. ncbi.nlm.nih.gov https://doi.org/10.31557/APJCP.2022.23.11.3869 |
| 20. Bahoush G, Nojoomi M. Frequency of Cytogenetic Findings and its Effect on the Outcome of Pediatric Acute Lymphoblastic Leukemia. 2019. ncbi.nlm.nih.gov https://doi.org/10.5455/medarh.2019.73.311-315 |
| 21. P. M. Douglas S, K. Lahtinen A, R. Koski J, Leimi L et al. Enrichment of cancer-predisposing germline variants in adult and pediatric patients with acute lymphoblastic leukemia. 2022. ncbi.nlm.nih.gov https://doi.org/10.1038/s41598-022-14364-x |
| 22. L. Wiemels J, M. Walsh K, J. de Smith A, Metayer C et al. GWAS in childhood acute lymphoblastic leukemia reveals novel genetic associations at chromosomes 17q12 and 8q24.21. 2018. ncbi.nlm.nih.gov https://doi.org/10.1038/s41467-017-02596-9 |
| 23. Pasha F, Urbančič D, Maxhuni R, Krasniqi S et al. Prevalence and Treatment Outcomes of Childhood Acute Lymphoblastic Leukemia in Kosovo. 2024. ncbi.nlm.nih.gov https://doi.org/10.3390/cancers16111988 |
| 24. M Ries N, LeGrandeur J, Caulfield T. Handling ethical, legal and social issues in birth cohort studies involving genetic research: responses from studies in six countries. 2010. ncbi.nlm.nih.gov https://doi.org/10.1186/1472-6939-11-4 |
| 25. Lautner-Csorba O, Gézsi A, J. Erdélyi D, Hullám G et al. Roles of Genetic Polymorphisms in the Folate Pathway in Childhood Acute Lymphoblastic Leukemia Evaluated by Bayesian Relevance and Effect Size Analysis. 2013. ncbi.nlm.nih.gov https://doi.org/10.1371/journal.pone.0069843 |
| 26. Lautner-Csorba O, Gézsi A, F Semsei Ágnes, Antal P et al. Candidate gene association study in pediatric acute lymphoblastic leukemia evaluated by Bayesian network based Bayesian multilevel analysis of relevance. 2012. ncbi.nlm.nih.gov https://doi.org/10.1186/1755-8794-5-42 |
| 27. Lv M, Liu Y, Liu W, Xing Y, Zhang S. Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives. Front. Immunol. 2022;13:921894. https://doi.org/10.3389/fimmu.2022.921894 |
| 28. Alkayed K, Al Hmood A, Madanat F. Prognostic effect of blood transfusion in children with acute lymphoblastic leukemia. Blood Res. 2013;48:133-138. https://doi.org/10.5045/br.2013.48.2.133 |
| 29. Jabbour E, Short NJ, Jain N, Haddad FG, et al. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J. Hematol. Oncol. 2023;16:22. https://doi.org/10.1186/s13045-023-01409-5 |
| 30. Cooper SL, Brown PA. Treatment of Pediatric Acute Lymphoblastic Leukemia. Pediatr. Clin. N. Am. 2015;62:61-73. https://doi.org/10.1016/j.pcl.2014.09.006 |
| 31. Gupta S, Dai Y, Chen Z, et al. Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: Secondary analyses of eight Children's Oncology Group cohort trials. Lancet Haematol. 2023;10:e129-e141. https://doi.org/10.1016/S2352-3026(22)00371-4 |
| 32. Ma H, Sun H, Sun X. Survival improvement by decade of patients aged 0-14 years with acute lymphoblastic leukemia: A SEER analysis. Sci. Rep. 2014;4:4227. https://doi.org/10.1038/srep04227 |
| 33. Pedrosa F, Coustan-Smith E, Zhou Y. et al. Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: Long-term results of the Recife RELLA05 pilot study. Blood. 2020;135:1458-1466. https://doi.org/10.1182/blood.2019004215 |
.
Permissions
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in American Journal of BioMedicine are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.